MedTrace Logo

The Effect of Daily Consumption of Extra Virgin Olive Oil on Blood Glucose Among Diabetic Patients

NCT03447301 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2018-02-27

No results posted yet for this study

Summary

Saudi Arabia has the highest prevalence (24%) of type 2 diabetes mellitus (T2DM) among the modern nation states in the world. In addition, majority of Saudi diabetic patient do not have their blood glucose controlled. Data suggests that diet, rich in olive oil and nuts, significantly reduces fasting plasma glucose and HbA1c (glycated hemoglobin). Olive oil has been associated with weight reduction as well as improvements in lipid profile (increase in high density (HDL) and decrease in low-density lipoprotein (LDL)). No randomized controlled trial has specifically examined the effect of olive oil as a supplement on blood glucose among diabetics. The study objective is to test the effect of daily consumption (30 mL) of extra-virgin olive oil (EVOO) on HbA1c among patients with type 2 diabetes.

Conditions

Interventions

DIETARY_SUPPLEMENT

Extra virgin olive oil (30mL daily)

Intervention arm will take 30 mL of Extra virgin olive oil daily.

Sponsors & Collaborators

  • Qassim University

    collaborator OTHER

  • Ministry of Health, Saudi Arabia

    collaborator OTHER_GOV

  • Sulaiman AlRajhi Colleges

    lead OTHER

Principal Investigators

  • Nazmus Saquib, PhD · Sulaiman Al-Rajhi Colleges

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-25
Primary Completion
2018-08-25
Completion
2018-12-25

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03447301 on ClinicalTrials.gov